7Suppliers
6Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Neumora Therapeutics, Inc. (NMRA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships
3Distinct source URLs
9High confidence
0.783Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Neumora Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
AMGN Amgen Inc. 90% Reciprocal relationship from AMGN graph: Reciprocal relationship from NMRA graph: Additionally, Amgen purchased 12.7 million shares of our Series A-2 Preferred Stock at a purchase price of $7.85 per …
AMGN Amgen Inc. 90% Additionally, Amgen purchased 12.7 million shares of our Series A-2 Preferred Stock at a purchase price of $7.85 per share, for total consideration of $100.0 million.
VANDERBILT VANDERBILT 90% In November 2023 and July 2025, a $2.0 and $5.0 million, respectively, development milestone was paid to Vanderbilt under the Vanderbilt License Agreement.
BLACKTHORN-THERAPEUTICS-INC BLACKTHORN-THERAPEUTICS-INC 85% The Company acquired BlackThorn for its in-process research and development programs, including an antagonist of the kappa opioid receptor ('navacaprant' or 'NMRA-140') for the treatment of MDD and a…
TSRI TSRI 80% Pursuant to the 2015 TSRI License Agreement, TSRI granted us a worldwide, exclusive license under certain patent rights and a worldwide, non-exclusive license under certain know-how relating to TSRI'…
MPLT MapLight Therapeutics, Inc. 72% Reciprocal relationship from MPLT graph: . Following any such strategic transaction, we may not achieve any expected synergies to justify the transaction. For example, such transactions may require u…
NBP NovaBridge Biosciences 72% Reciprocal relationship from NBP graph: rough various potential sources, such as equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our produ…

Neumora Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
MPLT MapLight Therapeutics, Inc. 72% Reciprocal relationship from MPLT graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from MPLT graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from MPLT g…
XENE Xenon Pharmaceuticals Inc. 72% Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will…
ASSETS-BLACKTHORN-THERAPEUTICS-INC ASSETS-BLACKTHORN-THERAPEUTICS-INC 62% linical costs 15,956 $ 11,606 Compensation and benefits 11,494 9,975 Other 724 $ 326 Professional services 614 2,686 Total accrued liabilities $ 28,788 $ 24,593 7. Acquisitions of Assets BlackThorn T…
BLACKTHORN-THERAPEUTICS-INC BLACKTHORN-THERAPEUTICS-INC 62% linical costs 15,956 $ 11,606 Compensation and benefits 11,494 9,975 Other 724 $ 326 Professional services 614 2,686 Total accrued liabilities $ 28,788 $ 24,593 7. Acquisitions of Assets BlackThorn T…
K2-HEALTHVENTURES-LLC K2-HEALTHVENTURES-LLC 62% incentive for employees, directors, and service providers. The Company accounts for all stock-based awards based on their fair value on the date of the grant. For stock-based awards with service only…
RESEARCH-VENTURES-LIMITED RESEARCH-VENTURES-LIMITED 62% . In addition, the Company also has an exclusive option to negotiate an exclusive license to certain patent rights conceived or developed by Vanderbilt in the course of carrying out the sponsored res…

Neumora Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
NMRA-DEBT-20260 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.
NMRA-DEBT-11312 Warrants outstanding: 1613000 90% xbrl warrant detail from xbrl 2022-12-31.
NMRA-DEBT Debt stack $112.9M 90% Market cache reports total debt of $112.9M.

Neumora Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Neumora Therapeutics, Inc..

Neumora Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
NMRA-OWNER-PERCEPTIVE-ADVISORS-LLC PERCEPTIVE ADVISORS LLC 90% 13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 117 tracked holders.

Neumora Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
XENE Xenon Pharmaceuticals Inc. 100.00 1 ['customer']
AMGN Amgen Inc. 100.00 1 ['supplier']
EH EHang Holdings Limited 100.00 2
ABT Abbott Laboratories 100.00 2
BMY Bristol-Myers Squibb Company 100.00 2
BMYMP Bristol-Myers Squibb Co 100.00 2
EM Smart Share Global Limited 100.00 2
NBIX Neurocrine Biosciences, Inc. 100.00 2
NBP NovaBridge Biosciences 100.00 1 ['supplier']
PRE Prenetics Global Limited 100.00 2
MPLT MapLight Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
SNYNF Sanofi 100.00 2
SBMFF Sino Biopharmaceutical Limited 100.00 2
JNJ Johnson & Johnson 100.00 2
LBRX LB Pharmaceuticals Inc 100.00 2
CUZ Cousins Properties Incorporated 50.00 2
HBIO Harvard Bioscience, Inc. 50.00 2
SUPN Supernus Pharmaceuticals, Inc. 50.00 2
NAUT Nautilus Biotechnology, Inc. 50.00 2
IMNM Immunome, Inc. 50.00 2
🔐
NMRA
Unlock NMRA Supply Chain Data
Verified relationships include:
AMGNAmgen Inc.Supplier90%
AMGNAmgen Inc.Supplier90%
MPLTMapLight Therapeutics, Inc.Customer72%
XENEXenon Pharmaceuticals Inc.Customer72%
+13 more relationships locked
Subscribe, View plans →